HRT and GLP-1 Medications: Different Treatments, Sometimes Part of the Same Plan

Menopause symptoms and weight concerns can arrive together. That does not mean they have the same treatment. Menopause hormone therapy, often called HRT, and GLP-1 medications address different clinical needs. A thoughtful plan starts by asking what each treatment is meant to accomplish.

An interesting association, with important limits

A 2024 retrospective study followed 106 postmenopausal women receiving semaglutide for overweight or obesity. Sixteen used hormone therapy; 90 did not. At 12 months, the groups had average total body weight reductions of approximately 16% and 12%, respectively. The association persisted after statistical adjustment. [1]

This was a small observational comparison, not a randomized trial of adding HRT. The groups differed, and adjustment cannot remove every difference. It does not establish that starting hormone therapy makes semaglutide work better, nor that the same result applies to every GLP-1 medication or every patient.

Give each treatment a clear purpose

Hormone therapy decisions depend on symptoms, medical history, treatment type and individual risks. A 2026 clinical review emphasizes that menopause hormone therapy should be used for established menopause-related indications, rather than prescribed or marketed as an obesity treatment. It also describes the evidence for combination benefits as preliminary. [2]

For someone who independently has a reason to consider both treatments, it can make sense to discuss them together. That discussion should include realistic goals and how benefits, side effects and follow-up will be assessed. The evidence does not support treating HRT as a required companion to a GLP-1 prescription.

Questions to bring to a visit

What symptoms are we treating? Do I have an independent indication for hormone therapy? What makes a weight-management medication appropriate for me? How will we judge whether the plan is helping?

The goal is a plan that fits your health, rather than a promise that one prescription will unlock another.

Sources

1. Hurtado et al., Menopause, 2024; retrospective cohort.

2. Younglove, Obesity Pillars, 2026; clinical review, not a new randomized trial.

Educational information, not individualized medical advice. Physician review required before publication.